Eluvia drug-eluting Vascular Stent System for the Treatment of Symptomatic Femoropopliteal Lesions

Abstract

Endovascular options are increasingly recognized as primary treatments for lower extremity peripheral arterial disease inadequately responsive to noninvasive therapy. Options include balloon angioplasty and stent implantation, and newer technologies incorporate drug coatings to prevent restenosis and reduce the need for reintervention. The Eluvia drug-eluting vascular stent system (Boston Scientific, MA, USA) was designed with a biocompatible fluoropolymer coating to allow for drug elution over time. Initial clinical results demonstrate promising efficacy in terms of sustained femoropopliteal artery patency along with a good safety profile. This review summarizes the existing clinical literature on treatment of femoropopliteal artery lesions with Eluvia, and outlines the continuing research program.

Keywords: :

• drug-eluting stent
• paclitaxel
• peripheral artery disease
• popliteal artery
• superficial femoral artery

Acknowledgements

The authors thank E Davis (Boston Scientific, MN, USA) for writing assistance.

Financial & competing interests disclosure

S Müller-Hülsbeck serves as a consultant for Boston Scientific, and has received consulting fees, speaker honoraria and support for accommodation and traveling when presenting BSC-related data. T Zeller serves as a consultant for Boston Scientific, Cook, Medtronic, WL Gore, Veryan, Spectranetics, Trireme, and Terumo and has received consulting fees, speaker honoraria and support for accommodation and traveling from the same companies. H Schroë serves as a consultant for Boston Scientific, and has received consulting fees, speaker honoraria and support for accommodation and traveling when presenting BSC-related data. J Diaz-Cartelle is an employee of and owns stock in Boston Scientific Corporation. WA Gray has received grant/research support from Boston Scientific and Medtronic, and consulting fees and/or honoraria from Boston Scientific, Medtronic and CSI. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was utilized in the production of this manuscript.